开设账户
模拟账户
关于我们
即时报价及新闻
市场分析
财经日历
每日市场分析
交易平台
下载及介绍
使用教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
繁
简
EN
客户登入
开设账户
模拟账户
繁
简
EN
客户登入
开设账户
模拟账户
关于我们
上志国际介绍
上志国际优势
即时报价及新闻
即时报价
即时新闻
市场分析
财经日历
市场分析
交易平台
平台特点
平台教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
关于我们
交易细则
贵金属市场
交易平台
市场分析
推广和资讯
常见问题
联络我们
繁
简
EN
Kiuchi says Japan's economy continues a moderate recovery.
2026-08-17
Kiuchi says Japan's economy continues a moderate recovery.
返回
其他消息
2026-08-17
Foshan Housing Provident Fund Management Center announced the city will raise the minimum contribution floor from Sept. 1, 2026. The contribution base minimum is set to Foshan’s on-the-job minimum wage of 2,300 yuan. Employer and employee monthly minimum contributions are each 115 yuan, for a combined minimum of 230 yuan. Flexible/self-employed participants face a monthly minimum contribution of 230 yuan.
Foshan Housing Provident Fund Management Center announced the city will raise the minimum contribution floor from Sept. 1, 2026. The contribution base minimum is set to Foshan’s on-the-job minimum wage of 2,300 yuan. Employer and employee monthly minimum contributions are each 115 yuan, for a combined minimum of 230 yuan. Flexible/self-employed participants face a monthly minimum contribution of 230 yuan.
2026-08-17
Aug 17 — AstraZeneca said Tezspire (tezepelumab) is now commercially available in China. In March 2026 tezepelumab was approved in China, based on positive Phase III DIRECTION and WAYPOINT trials, for two indications: maintenance treatment of severe asthma in adults and adolescents aged 12 and over; and, as an add-on to intranasal corticosteroids, treatment of adult chronic rhinosinusitis with nasal polyps (CRSwNP) not adequately controlled by systemic corticosteroids and/or surgery.
Aug 17 — AstraZeneca said Tezspire (tezepelumab) is now commercially available in China. In March 2026 tezepelumab was approved in China, based on positive Phase III DIRECTION and WAYPOINT trials, for two indications: maintenance treatment of severe asthma in adults and adolescents aged 12 and over; and, as an add-on to intranasal corticosteroids, treatment of adult chronic rhinosinusitis with nasal polyps (CRSwNP) not adequately controlled by systemic corticosteroids and/or surgery.
Chat with us
, powered by
LiveChat